Company profile: AbilityPharma
1.1 - Company Overview
Company description
- Provider of oncology drug discovery and development of therapeutics targeting cell membranes to address unmet needs. Focused on lung and pancreatic cancers, it develops ABTL0812, a first-in-class autophagy inducer in phase 2b trials for metastatic pancreatic cancer. Includes R&D on cytotoxic autophagy, funding partnerships, and FDA/EMA Orphan Drug Designations for pancreatic and biliary cancers and pediatric neuroblastoma.
Products and services
- ABTL0812: First-in-class autophagy inducer drug in phase 2b trials for metastatic pancreatic cancer, potentiating chemotherapy efficacy without added toxicity and advancing toward improved outcomes
- Clinical Trials: Multinational phase 2b studies of ABTL0812 in metastatic pancreatic cancer across Spain, USA, France, and Israel, aiming to demonstrate greater efficacy than current treatments
- Research and Development: Cell-membrane-targeted therapeutics are engineered to induce cytotoxic autophagy selectively in cancer cells, addressing unmet oncological needs including lung and pancreatic cancers
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to AbilityPharma
Sierra Oncology
HQ: United States
Website
- Description: Provider of targeted cancer therapeutics in clinical development, focused on rare forms of cancer. Leverages deep scientific expertise to identify compounds that target root causes of disease and advances therapies using an evidence-based approach.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sierra Oncology company profile →
iOnctura
HQ: Switzerland
Website
- Description: Provider of clinical-stage biopharmaceutical therapies targeting immunosuppression in the tumor microenvironment to improve immune checkpoint therapies. Pipeline includes Roginolisib (IOA-244), a PI3Kδ inhibitor in Phase Ib/II for solid tumors and hematological malignancies; IOA-289, an autotaxin inhibitor in Phase Ib/II for pancreatic and other CAF-driven tumors; and preclinical IOA-359 (TGF-β) and IOA-237 (CD73 mAb).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full iOnctura company profile →
TheraPharm
HQ: Germany
Website
- Description: Provider of monoclonal antibody-based diagnostic and therapeutic biotechnology solutions in hematology, specializing in research, development, and manufacturing for targeted radiation of hematopoietic malignant and non-malignant diseases and lymphoproliferative diseases, conditioning for allogeneic stem cells, and diagnostics of inflammatory diseases and bone marrow metastases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TheraPharm company profile →
TechniScan Medical Systems
HQ: United States
Website
- Description: Provider of ultrasound breast imaging and diagnostic systems, developing and commercializing systems for breast imaging and diagnosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TechniScan Medical Systems company profile →
T3 Pharmaceuticals
HQ: Switzerland
Website
- Description: Provider of innovative bacterial cancer therapies using engineered live bacteria to deliver immune-modulating proteins directly to cancer cells and the tumor micro-environment. Offers a proprietary bacterial cancer therapy platform and develops T3P-Y058-739, a lead candidate delivering proteins into solid tumors to induce a specific immune response.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full T3 Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for AbilityPharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to AbilityPharma
2.2 - Growth funds investing in similar companies to AbilityPharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for AbilityPharma
4.2 - Public trading comparable groups for AbilityPharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →